Tangential flow filtration (TFF) using ultrafiltration membranes is commonly used for the final formulation and concentration of monoclonal antibodies. Injection of liquid formulations is often the preferred method of administration for these therapeutics. In cases where high dosages are required, manufacturers frequently target high concentration liquid formulations which can result in high viscosity solutions. Highly concentrated protein solutions have challenges associated with formulation. This webinar presents the formulation challenges that are associated with plausible risk mitigation strategies to overcome such formulation challenges.
In this webinar you will learn about:
- High concentration UF-DF optimization
- Scaling up the UF-DF step
- Models to explain buffer offsets
- Process Development to mitigate buffer offsets
Speaker
Subhasis Banerjee, Ph.D.
Merck
Principal Bioprocessing Application Expert
Subhasis supports the technical consultation for downstream processing for the APAC region. He has a Ph.D. in biochemistry with post-doctoral experience from The Ohio State University, Columbus, USA. He has contributed to several publications in international peer-reviewed journals and conducted presentations in numerous national and international Conferences.
Pharma and biopharma manufacturing
- Downstream Processing
Duration:1h 14min
Language:English
Session 1:presented March 23, 2021
To continue reading please sign in or create an account.
Don't Have An Account?